Literature DB >> 8910441

Thyroid hormone receptor variant alpha2. Role of the ninth heptad in dna binding, heterodimerization with retinoid X receptors, and dominant negative activity.

Y Z Yang1, M Burgos-Trinidad, Y Wu, R J Koenig.   

Abstract

Thyroid hormone receptors bind DNA with highest affinity as heterodimers with retinoid X receptors, and such heterodimers generally are thought to be the biological mediators of thyroid hormone action. An alternative splice product of the thyroid hormone receptor alpha gene, thyroid hormone receptor variant alpha2, does not bind thyroid hormone and functions as a weak dominant negative inhibitor of thyroid hormone action. Thyroid hormone receptor variant alpha2 is missing one-half of the ninth heptad, a region of the bona fide receptor thought to be important for heterodimerization with retinoid X receptors. The role of the ninth heptad in heterodimerization has been evaluated further. Thyroid hormone receptor variant alpha2-retinoid X receptor heterodimers form on a subset of direct repeat response elements but not on palindromic or inverted palindromic elements. Restoration of the missing ninth heptad sequence is critical for restoring heterodimerization on the palindromic DNA, but either the ninth heptad amino acids or a stretch of alanines is equally able to restore heterodimerization on the inverted palindrome. Thus, the role of the ninth heptad in heterodimerization differs on direct repeat, palindromic, and inverted palindromic response elements, suggesting that the protein-protein interactions differ on each of these elements. The dominant negative activity of thyroid hormone receptor variant alpha2 requires DNA binding, but the relatively weak nature of the dominant negative activity is only partially explained by the weak DNA binding.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8910441     DOI: 10.1074/jbc.271.45.28235

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Region-specific effects of hypothyroidism on the relative expression of thyroid hormone receptors in adult rat brain.

Authors:  Caterina Constantinou; Marigoula Margarity; Theony Valcana
Journal:  Mol Cell Biochem       Date:  2005-10       Impact factor: 3.396

2.  Differential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor regulates transcriptional repression.

Authors:  J Zhang; I Zamir; M A Lazar
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

3.  Structure and expression of two nuclear receptor genes in marsupials: insights into the evolution of the antisense overlap between the α-thyroid hormone receptor and Rev-erbα.

Authors:  Brandon C Rindfleisch; M Scott Brown; John L VandeBerg; Stephen H Munroe
Journal:  BMC Mol Biol       Date:  2010-12-10       Impact factor: 2.946

Review 4.  TRα2-An Untuned Second Fiddle or Fine-Tuning Thyroid Hormone Action?

Authors:  Georg Sebastian Hönes; Nina Härting; Jens Mittag; Frank J Kaiser
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

5.  Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)α1 and TRα2: clinical, biochemical, and genetic analyses of three related patients.

Authors:  Carla Moran; Maura Agostini; W Edward Visser; Erik Schoenmakers; Nadia Schoenmakers; Amaka C Offiah; Ken Poole; Odelia Rajanayagam; Greta Lyons; David Halsall; Mark Gurnell; Dionisios Chrysis; Alexandra Efthymiadou; Charles Buchanan; Simon Aylwin; Krishna K Chatterjee
Journal:  Lancet Diabetes Endocrinol       Date:  2014-06-23       Impact factor: 32.069

Review 6.  Resistance to thyroid hormone due to defective thyroid receptor alpha.

Authors:  Carla Moran; Krishna Chatterjee
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-07-30       Impact factor: 4.690

7.  TR alpha 2 exerts dominant negative effects on hypothalamic Trh transcription in vivo.

Authors:  Hajer Guissouma; Rym Ghaddab-Zroud; Isabelle Seugnet; Stéphanie Decherf; Barbara Demeneix; Marie-Stéphanie Clerget-Froidevaux
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.